PierianDx and Pillar Biosciences Announce Partnership to Support Precision Cancer Care
14.10.2020 15:00:00 EEST | Business Wire | Press release
PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx clinical genomic report in combination with its cancer profiling assays. Under the agreement, PierianDx will integrate the Pillar Biosciences PiVAT® bioinformatics pipeline in the PierianDx environment to provide users with an accelerated implementation, including assay-specific variant filters, to produce best-in-class clinical genomics reports and enable a complete sample-to-answer solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005056/en/
Laboratories worldwide use Pillar Biosciences’ assays to detect pivotal genetic variants for cancer and other diseases. Pillar Biosciences’ targeted panels utilize a proprietary enrichment chemistry, SLIMamp®, that enables rapid, automated amplification of overlapping amplicons in a single tube using minimal sample inputs. Pillar Biosciences’ complementary bioinformatics pipeline, PiVAT®, is optimized for efficiency, reducing reflex testing and enabling low-frequency variant calling for every type of variant while consuming limited computing resources. PierianDx provides the Clinical Genomics Workspace™, which consists of intuitive software and a robust clinical Knowledgebase that transforms variant information into a highly-structured and comprehensive physician-ready report.
Streamlining NGS along with clinical genomic interpretation and reporting, especially for sophisticated panels, remains time-consuming and challenging. By packaging the Pillar Biosciences panels with the PierianDx report, the result will be an out-of-the-box clinical genomic report that is optimized for each assay. Furthermore, the solution will be available to customers globally through secure, and in the case of European regions, Global Data Protection Regulation (GDPR)-compliant, cloud instances. As a result, laboratories and healthcare organizations worldwide will have a highly reliable method for providing these tests to enable precision diagnostics and treatments for their patients.
“The assays from Pillar Biosciences provide robust detection for all variant types in a simplified workflow,” states Gang Song, PhD, CEO of Pillar Biosciences. “By optimizing variant filters and integrating with the PiVAT pipeline, PierianDx is streamlining interpretation and reporting, which adds substantial value for our customers.”
Rakesh Nagarajan, MD, PhD and Founder and Chief Technical and Visionary Officer of PierianDx, adds, “We are thrilled to provide this support for the Pillar Biosciences assays. As the market shifts to more sensitive assays in the LDT space and leading assay manufacturers seek in vitro diagnostic (IVD) approval, we are committed to addressing challenges that arise from even greater complexity in the interpretation and reporting process.”
About PierianDx
Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary germline diseases. www.pieriandx.com.
About Pillar Biosciences
Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automatable variant detection technologies deliver robust results with rapid turnaround times through streamlined NGS workflows. Our SLIMamp®– and PiVAT®-based products help high-throughput reference laboratories and clinical oncology laboratories make precision medicine practical by boosting their diagnostic productivity.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005056/en/
Contact information
Media contact for PierianDx:
Garreth Hippe
info@pieriandx.com
Media contact for Pillar Biosciences:
William Wright
info@pillar-biosciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Skechers Enters Super Shoe Era With Innovative Skechers AERO Elite1.10.2026 15:20:00 EEST | Press release
Skechers is redefining what it means to run fast with the Skechers AERO Elite. The latest addition to the innovative Skechers AERO Series makes its global racing debut today—marking a landmark moment as the performance brand’s first super shoe. Engineered to perform from 5Ks to marathons, the design minimizes weight and maximizes responsiveness, all while delivering Skechers’ signature comfort. The AERO Elite is built to win with the performance runners at any level need to go further, faster, and achieve that next personal record. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001865320/en/ Introducing the Skechers AERO Elite, the brand’s first super shoe designed for racing. “The Skechers AERO Elite is the culmination of years of elite-level running innovation—our most technically advanced running shoe to date and a direct statement of intent as we look ahead to the 2028 Summer Games in Los Angeles,” said Catherine Zou,
Visa Data Shows Stablecoins Gaining Traction in Business Payments1.10.2026 15:00:00 EEST | Press release
Today, Visa (NYSE: V) shared new data showing the growing adoption of stablecoins across business payments and commercial card programs, underscoring how stablecoins are increasingly being used as financial infrastructure. The findings come as businesses, financial institutions and payment providers increasingly explore stablecoins for settlement, treasury management, payouts and cross-border commerce. New Visa data shows: Approximately 17% of stablecoin-linked card volume in FY26 year-to-date occurred across business and commercial card programs. Visa today supports more than 160 stablecoin-linked card programs spanning consumer, business and commercial card activity. Payments volume across these programs has grown nearly 200% year over year. Businesses are increasingly exploring stablecoins for settlement, treasury management, payouts and cross-border commerce. "Businesses aren't looking for new payment technologies for the sake of innovation. They’re looking for trusted, reliable wa
New Research: Organizations with Strong Process Context 5x More Likely to Deliver Successful AI Outcomes1.10.2026 15:00:00 EEST | Press release
Organizations with strong process context are five times more likely to report very successful AI outcomes, according to new research from The Hackett Group® and ARIS, highlighting the critical role business understanding plays in enabling enterprises to deploy agentic AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001144480/en/ The Process Context Study 2026 found that companies experienced with strong process context were 5x more likely to be seeing successful outcomes from AI The Process Context Study 2026 examines how prepared Global 2000 companies are to deploy agents into core business processes and how process context is key to agents operating reliably and securely at enterprise-level, driving measurable new business value. The findings expose a significant gap between enterprise AI ambition and current operational readiness: 86% of respondents believe agents cannot be deployed reliably without proces
NetApp Recognizes Winners of 2026 North America Partner Awards1.10.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced at NetApp INSIGHT 2026 the winners of its North America Partner Awards for Fiscal Year 2026 (FY’26). NetApp’s strategic partnerships aid in providing NetApp products and solutions to solve the business challenges of their joint customers. The North America Partner Award winners have been instrumental in helping customers to build an Intelligent Data Infrastructure through the NetApp Platform, that can securely evolve and scale with their needs by driving sales of NetApp’s solutions and services. Each winning partner has demonstrated a thorough understanding of the NetApp portfolio and has proven their ability to leverage NetApp’s innovative solutions and services to give customers the confidence they need to overcome today’s biggest technology challenges. “Now more than ever, we must empower customers with AI-ready data that is secure by default and built for hybrid environments so they can achieve the
Moody’s Analytics and Allvue Launch Credit Risk Model to Identify Early Signs of Borrower Stress in Private Credit1.10.2026 15:00:00 EEST | Press release
Moody’s Corporation (NYSE: MCO), a global leader in risk assessment and credit analytics, and Allvue Systems, LLC, a leading technology and data provider for private capital markets, today announced the launch of the Moody’s Analytics EDF-X Private Credit Model, a new forward-looking credit risk model purpose-built for the private credit market. Built on Moody’s deep credit expertise and Allvue’s private credit performance data, the model identifies early signals of borrower stress, such as covenant waivers and payment-in-kind arrangements, well before they show up as missed payments or defaults. Moody’s projects private credit to approach $4 trillion in assets by 2030, and investors and lenders are increasingly seeking earlier visibility on where risk is building across portfolios. Unlike public credit markets where participants have the benefit of access to published credit ratings, financial disclosures, and transparent pricing, private credit often relies on proprietary credit asse
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom